Fosamax

Fosamax

The primary focus of this Litigation Group is on Fosamax®. However, the group also intends to cover other Bisphosphonate drugs (e.g. Aredia, Zometa).

Fosamax® (Alendronate) is a compound that alters the cycle of bone formation and breakdown in the body. Fosamax® is manufactured by Merck & Co. In December 2004, doctors at Long Island Jewish Medical Center (LIJ) announced that they had discovered a link between bisphosphonate drugs and osteonecrosis of the jaw (ONJ), or literally, death of the jaw bone tissue. The report prompted both the U.S. Food and Drug Administration (FDA) and bisphosphonate drug makers to issue updated warnings to doctors. Merck stated it received a request from the FDA to update the label in January 2005. There is currently an MDL in S.D. NY (MDL 1789), and there is expected to be significant litigation in State Court in New Jersey.

Formed February 2007.

The Fosamax® Litigation Group has a list server and document library where members can share information, documents, and pertinent information.

Meetings:

AAJ Annual and Winter Conventions, or as needed by group members.

Membership:

Open to Regular, Sustaining, Life, Leaders Forum, and President's Club members.

Dues:

$300/first two attorneys, $100/additional member